| Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia. | |
| | |
MedLine Citation:
|
PMID: 16133538 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
When determining the carboplatin dosage from the Calvert formula, there are a lack of data when evaluating patients with cachexia or body mass index (BMI)>or=27. If the Cockcroft and Gault (C-G) creatinine clearance (CrCl) equation is utilized and substituted for glomerular filtration rate in the Calvert formula, the chance for inaccurate dosing occurs especially in these populations. Therefore, the purpose of this study is to evaluate and compare the target carboplatin area under the concentration (AUC) with the actual AUC achieved in cachectic or BMI>or=27 patients. In a prospective manner, we evaluated 19 patients with a BMI>or=27 and nine cachectic patients. In the C-G equation to determine creatinine clearance, the adjusted body weight was used for BMI>or=27 patients and serum creatinine value of 70.7 microM (0.8 mg/dl) for the cachectic patients. The carboplatin dose was calculated, administered to the patients, and subsequent carboplatin blood samples were obtained for pharmacokinetic determination. Once the AUC was determined, the results were compared with the expected outcomes from the modified C-G CrCl equation for the Calvert formula, Chatelut and Bénézet equations. The results demonstrated that the modified C-G CrCl equation for the Calvert formula had less bias and more precision than using actual weight in the C-G CrCl equation or using the Chatelut and Bénézet equations. Using the actual weight in overweight and especially obese patients and using a serum creatinine<70.7 microM in cachectic patients will lead to overestimation of the carboplatin clearance and thus AUC. |
| | |
Authors:
|
Jon D Herrington; Hai T Tran; Mark W Riggs |
Related Documents
:
|
21219298 - Modulation of jak2 v617f allele burden dynamics by hydroxycarbamide in polycythaemia ve... 18588828 - Estimated creatinine clearance: a determinant prognostic factor in heart failure. 15730138 - Influence of fluid therapy on gentamicin pharmacokinetics in colic horses. 20089558 - Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib ... 20685688 - Congestion in chronic systolic heart failure is related to renal dysfunction and increa... 9290518 - Effectiveness of cholecystokinin-stimulated cholescintigraphy in the diagnosis and trea... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article Date: 2005-08-25 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 57 ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2006 Jan |
Date Detail:
|
Created Date: 2005-12-12 Completed Date: 2006-01-17 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: Germany |
Other Details:
|
Languages: eng Pagination: 241-7 Citation Subset: IM |
Affiliation:
|
Department of Clinical Pharmacy, Scott & White Memorial Hospital, 2401 South 31st Street, Temple, TX 76508, USA. jherrington@swmail.sw.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / administration & dosage, pharmacokinetics* Area Under Curve Body Mass Index Cachexia / complications* Carboplatin / administration & dosage, pharmacokinetics* Female Forecasting Humans Male Middle Aged Models, Theoretical |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 41575-94-4/Carboplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies.
Next Document: Progressive accumulation of ubiquitin and disappearance of alpha-synuclein epitope in multiple syste...